Table 1.
Renal parameters | NS | HS | NS + SCH | HS + SCH |
---|---|---|---|---|
Water intake (mL day−1) | 15.59 ± 0.85 | 26.54 ± 2.18a | 13.5 ± 0.85 | 25.67 ± 1.43a |
Plasma Na+ (mmol L−1) | 139.5 ± 1.5 | 142.33 ± 1.86 | 140 ± 1.8 | 141 ± 2.1 |
Plasma K+ (mmol L−1) | 3.15 ± 0.05 | 3.7 ± 0.36 | 3.25 ± 0.07 | 3.5 ± 0.45 |
Diuresis, (mL day−1 100 g bwt−1) | 3.55 ± 0.19 | 11.67 ± 1.54a | 3.13 ± 0.11 | 3.97 ± 0.49d |
Urinary Na+ excretion, (mmol day−1 100 g bwt−1) | 0.44 ± 0.09 | 3.95 ± 0.24a | 0.39 ± 0.06 | 1.32 ± 0.20b , d |
Urinary Dopamine, (ng day−1 100 g bwt−1) | 679 ± 24 | 1504 ± 94a | 670 ± 34 | 1562 ± 89c |
Results are expressed as the mean ± SEM (n = 7). Two‐way ANOVA showed a statistically significant interaction (P < 0.001) between the effects of HS and SCH treatment on diuresis and urinary Na+ excretion. High salt intake had a significant overall effect on urinary dopamine (P < 0.001). NS, normal salt intake; HS, high salt intake; SCH: D1‐like receptor antagonist SCH 23390. Bonferroni post‐test as follows:
P < 0.001 versus NS.
P < 0.01 versus NS+SCH.
P < 0.001 versus NS+SCH.
P < 0.001 versus HS.